Status: Not yet recruiting
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
This study is an open-label, multicenter, dose-escalation and dose-expansion, non-randomized phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SI-B036 bispecific antibody injection in patients with locally advanced or metastatic urological tumors and other solid tumors.
Participants needed: 30
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Sichuan Baili Pharmaceutical Co., Ltd.Updated: Aug 6, 2026Locations: 1
Eligibility criteria
Voluntarily sign the informed consent form and agree to comply with the protocol... [+14]
Use of chemotherapy, biotherapy, immunotherapy, or similar treatments within 4 w... [+23]